Introducing the Novartis Declaration for Patients

(2:36)

Manufacturing CAR-T Cell Therapies: The Novartis Approach

(2:14)

What is the Novartis next generation Technology Platforms strategy?

(2:12)

Long Live Life: Connecting with the Novartis Mission

(1:40)

The Novartis Commitment to Patients and Caregivers

(2:48)

Manufacturing CAR-T Cell Therapies: The Novartis Commitment to Patients

(58)

The Novartis Biome - a catalyst for impactful digital collaborations

(1:10)

A look inside the Genomics Institute of the Novartis Research Foundation

(3:4)

02/25/2025 - Hi-Risk/Recurrent/Advanced PCa Men \u0026 Caregivers

(2:18:52)

Novartis CEO Vas Narasimhan on The David Rubenstein Show

(24:7)

Le retour de la vengeance de la Macro | Swiss Bliss | Swissquote

(27:24)

Vas Narasimhan at the 2019 One Young World Summit

(9:8)

LATEST news for KIDNEY Disease - PROTEINURIA reducing MEDICINES and keto analogues - HOPE for #ckd

(10:4)

Novartis CEO Vas Narasimhan: Expect solid growth this year top and bottom line

(3:50)

ProTox 3.0: Toxicity Analysis of Nanoparticle Structure | Step-4 | Lecture 440 | Dr. Muhammad Naveed

(7:46)

Novartis CEO Vas Narasimhan: How to be a boss in an “unbossed” company

(25:17)

Goovis Art Review - The Future of Gaming, Entertainment \u0026 Productivity Has Arrived

(9:23)

Novartis CEO on Acquisitions, AI, Weight-Loss Drugs

(4:19)

Vas Narasimhan and author Dan Pink talk culture and leadership

(4:27)

Turning research advances into innovative medicines

(57)

The future of Novartis

(1:52)

Working with Multiple Sclerosis – A Novartis Intern’s Experience

(55)

Meet the Novartis Prague team...

(3:11)

Meet with David Hughes from the Novartis Malaria Initiative team

(1:6)

Novartis as a focused innovative medicines company

(54)

EP128 Harnessing Data Science for Cardiovascular Health with The Novartis Foundation

(40:50)

Novartis Access Defined

(48)

The #Novartis scheme: a story of corruption, crime and persecution

(5:57)

Founder Stories: Shreeram Aradhye, Chief Medical Officer at Novartis

(31:15)

Novartis Targets Cancer Genomics for Precision Medicine

(2:2)